SG Americas Securities LLC increased its position in shares of Amedisys Inc (NASDAQ:AMED) by 48.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,743 shares of the health services provider’s stock after buying an additional 1,226 shares during the quarter. SG Americas Securities LLC’s holdings in Amedisys were worth $235,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new position in shares of Amedisys during the first quarter worth about $123,000. CIBC Asset Management Inc bought a new position in shares of Amedisys during the second quarter worth about $230,000. Redmile Group LLC bought a new position in shares of Amedisys during the first quarter worth about $247,000. Suntrust Banks Inc. grew its holdings in shares of Amedisys by 2.0% during the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock worth $279,000 after buying an additional 107 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its holdings in shares of Amedisys by 1.8% during the first quarter. Municipal Employees Retirement System of Michigan now owns 6,370 shares of the health services provider’s stock worth $325,000 after buying an additional 110 shares in the last quarter. Institutional investors and hedge funds own 96.55% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/18/sg-americas-securities-llc-boosts-position-in-amedisys-inc-amed.html.

In other Amedisys news, Director Bruce D. Perkins bought 2,000 shares of Amedisys stock in a transaction dated Thursday, August 3rd. The stock was bought at an average cost of $46.60 per share, with a total value of $93,200.00. Following the completion of the acquisition, the director now directly owns 15,825 shares in the company, valued at approximately $737,445. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the completion of the transaction, the insider now directly owns 10,488 shares of the company’s stock, valued at $524,400. The disclosure for this sale can be found here. Corporate insiders own 2.80% of the company’s stock.

Amedisys Inc (NASDAQ AMED) opened at 52.03 on Monday. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91. The firm has a market capitalization of $1.76 billion, a PE ratio of 44.47 and a beta of 0.84. The company’s 50-day moving average price is $50.02 and its 200 day moving average price is $54.86.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The firm had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.42 EPS. On average, equities research analysts predict that Amedisys Inc will post $2.21 earnings per share for the current year.

AMED has been the subject of a number of research reports. BidaskClub upgraded Amedisys from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Bank of America Corporation initiated coverage on Amedisys in a report on Monday, August 21st. They set a “neutral” rating and a $55.00 price objective for the company. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $60.00 price objective on shares of Amedisys in a report on Friday. Mizuho downgraded Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a report on Wednesday, July 26th. Finally, Royal Bank Of Canada reiterated a “hold” rating and set a $56.00 price objective on shares of Amedisys in a report on Monday, June 5th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Amedisys has a consensus rating of “Hold” and a consensus price target of $56.44.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.